Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles

NMR in Biomedicine

Volumn 25, Issue 2, 2012, Pages 279-285

  Cai, Kejia ^a   Kiefer, Garry E ^b   Caruthers, Shelton D ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a   Winter, Patrick M ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cincinnati Children's Hospital ^*

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Fibrin; Fluorine; Nanoparticle; PARACEST

Indexed keywords

ATHEROSCLEROTIC PLAQUE; BACKGROUND SIGNALS; BOUND WATERS; CONTRAST AGENT; CONTRAST TO NOISE RATIO; DETECTION LIMITS; FIBRIN; IMAGE CONTRASTS; IN-VITRO; MATHEMATICAL MODELING; MOLECULAR IMAGING; NANOPARTICLE SURFACE; PARACEST; PARAMAGNETIC CHEMICAL-EXCHANGE-SATURATION- TRANSFERS; PARTICLE BINDING; PERFLUOROCARBONS; PHANTOM EXPERIMENT; SIGNAL INTENSITIES; SMALL MOLECULES; TARGET SURFACE; WATER EXCHANGE;

BIOMARKERS; CHELATION; FLUORINE; PARAMAGNETISM; SIGNAL DETECTION; WATER INJECTION;

NANOPARTICLES;

CONTRAST MEDIUM; FIBRIN; NANOPARTICLE; PARAMAGNETIC CHEMICAL EXCHANGE SATURATION TRANSFER AGENT; PERFLUOROCARBON NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTRAST; CONTROLLED STUDY; FLUORINE NUCLEAR MAGNETIC RESONANCE; IMAGE QUALITY; LIMIT OF DETECTION; MOLECULAR IMAGING; PRIORITY JOURNAL; SURFACE CHARGE; TRANSPORT KINETICS; WATER EXCHANGE KINETICS;

ANIMALS; BLOOD COAGULATION; CHELATING AGENTS; COMPUTER SIMULATION; CONTRAST MEDIA; DOGS; FIBRIN; FLUOROCARBONS; KINETICS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; SOLUBILITY; WATER;

EID: 84856022354     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1746     Document Type: Article

References (28)

1. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 2000; 143(1): 79-87.
2. Pikkemaat JA, Wegh RT, Lamerichs R, van de Molengraaf RA, Langereis S, Burdinski D et al. Dendritic PARACEST contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging 2007; 2(5): 229-239.
3. Aime S, Delli Castelli D, Terreno E. Supramolecular adducts between poly-L-arginine and [TmIIIdotp]: a route to sensitivity-enhanced magnetic resonance imaging-chemical exchange saturation transfer agents. Angew. Chem. Int. Ed Engl. 2003; 42(37): 4527-4529.
4. Ali MM, Yoo B, Pagel MD. Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol. Pharm. 2009; 6(5): 1409-1416.
5. Wu Y, Zhou Y, Ouari O, Woods M, Zhao P, Soesbe TC et al. Polymeric PARACEST agents for enhancing MRI contrast sensitivity. J. Am. Chem. Soc. 2008; 130(42): 13854-13855.
6. Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS et al. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn. Reson. Med. 2006; 56(6): 1384-1388.
7. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 2004; 52(6): 1255-1262.
8. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94(12): 3334-3340.
9. Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med. 2003; 50(2): 411-416.
10. Woessner DE, Zhang S, Merritt ME, Sherry AD. Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI. Magn. Reson. Med. 2005; 53(4): 790-799.
11. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104(11): 1280-1285.
12. Terreno E, Castelli DD, Cravotto G, Milone L, Aime S. Ln(III)-DOTAMGly complexes: a versatile series to assess the determinants of the efficacy of paramagnetic chemical exchange saturation transfer agents for magnetic resonance imaging applications. Invest. Radiol. 2004; 39(4): 235-243.
13. Woods M, Sherry AD. Engineering lanthanide complexes with controlled water exchange rates for magnetic resonance imaging. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2004; 7: 5254-5257.
14. Jaszberenyi Z, Sour A, Toth E, Benmelouka M, Merbach AE. Fine-tuning water exchange on Gd(III) poly(amino carboxylates) by modulation of steric crowding. Dalton Trans. 2005; (16): 2713-2719.
15. Kotek J, Lebduskova P, Hermann P, Vander Elst L, Muller RN, Geraldes CF et al. Lanthanide (III) complexes of novel mixed carboxylic-phosphorus acid derivatives of diethylenetriamine: a step towards more efficient MRI contrast agents. Chemistry 2003; 9(23): 5899-5915.
16. Laus S, Ruloff R, Toth E, Merbach AE. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents. Chemistry 2003; 9(15): 3555-3566.
17. Rudovsky J, Kotek J, Hermann P, Lukes I, Mainero V, Aime S. Synthesis of a bifunctional monophosphinic acid DOTA analogue ligand and its lanthanide(III) complexes. A gadolinium(III) complex endowed with an optimal water exchange rate for MRI applications. Org. Biomol. Chem. 2005; 3(1): 112-117.
18. Ali MM, Woods M, Suh EH, Kovacs Z, Tircso G, Zhao P et al. Albumin-binding PARACEST agents. J. Biol. Inorg. Chem. 2007; 12(6): 855-865.
19. Vasalatiy O, Zhao P, Woods M, Marconescu A, Castillo-Muzquiz A, Thorpe P et al. Strategies for labeling proteins with PARACEST agents. Bioorg Med Chem 2010.
20. Aime S, Botta M, Crich SG, Giovenzana GB, Pagliarin R, Piccinini M et al. Towards MRI contrast agents of improved efficacy. NMR relaxometric investigations of the binding interaction to HSA of a novel heptadentate macrocyclic triphosphonate Gd(III)-complex J. Biol. Inorg. Chem. 1997; 2: 470-479.
21. Aime S, Botta M, Fasano M, Crich SG, Terreno E. Gd(III) complexes as contrast agents for magnetic resonance imaging: a proton relaxation enhancement study of the interaction with human serum albumin J. Biol. Inorg. Chem. 1996; 1: 312-319.
22. Aime S, Chiaussa M, Digilio G, Gianolio E, Terreno E. Contrast agents for magnetic resonance angiographic applications: 1H and 17O NMR relaxometric investigations on two gadolinium(III) DTPA-like chelates endowed with high binding affinity to human serum albumin. J. Biol. Inorg. Chem. 1999; 4(6): 766-774.
23. Aime S, Gianolio E, Longo D, Pagliarin R, Lovazzano C, Sisti M. New insights for pursuing high relaxivity MRI agents from modelling the binding interaction of Gd(III) chelates to HSA. Chembiochem 2005; 6(5): 818-820.
24. Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 2002; 124(12): 3152-3162.
25. +-DOTAM-glycine (Gly)-phenylalanine (Phe). Magn. Reson. Med. 2008; 59(2): 374-381.
26. Zhang S, Malloy CR, Sherry AD. MRI thermometry based on PARACEST agents. J. Am. Chem. Soc. 2005; 127(50): 17572-17573.
27. Aime S, Barge A, Delli Castelli D, Fedeli F, Mortillaro A et al. Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn. Reson. Med. 2002; 47(4): 639-648.
28. Liu G, Li Y, Pagel MD. Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn Reson Med 2007; 58(6): 1249-1256.